Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
Auteurs principaux: | Sun Joo Cha, Kiyoung Kim |
---|---|
Format: | Article |
Langue: | English |
Publié: |
MDPI AG
2022-01-01
|
Collection: | Antioxidants |
Sujets: | |
Accès en ligne: | https://www.mdpi.com/2076-3921/11/2/195 |
Documents similaires
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
par: Erdi Şahin
Publié: (2018-03-01) -
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
par: Shivangi Garg, et autres
Publié: (2019-01-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
par: Hideki Houzen, et autres
Publié: (2021-07-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
par: Jin-Mo Park, et autres
Publié: (2022-07-01) -
Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
par: Chang Liu, et autres
Publié: (2024-10-01)